Clinical applications of recent molecular advances in urologic malignancies: No longer chasing a "mirage"?

Advances in Anatomic Pathology

Volumn 20, Issue 3, 2013, Pages 175-203

  Netto, George J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

biomarkers prognostics; genetics; Molecular; neoplasms; urologic

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; GLUTATHIONE TRANSFERASE P1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; PROTEIN TYROSINE KINASE; SORAFENIB; SURVIVIN; TRANSCRIPTION FACTOR ERG; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ALGORITHM; ANGIOGENESIS; AUTOPHOSPHORYLATION; BLADDER; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 9; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; GENOMIC INSTABILITY; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HORMONE RELEASE; HUMAN; KIDNEY CANCER; LYMPH VESSEL METASTASIS; MOLECULAR DIAGNOSIS; ONCOGENE MYC; OVARY FOLLICLE DEVELOPMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLOIDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE SECRETION; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TELOMERE; TESTIS TUMOR; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER;

ADENOCARCINOMA; DNA, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84876229661     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182863f80     Document Type: Review

References (367)

1. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
3. Prowatke I, Devens F, Benner A, et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue micro-arrays. Br J Cancer. 2007;96:82-88.
4. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes ofprostate cancer. Proc Natl Acad Sci USA. 2004;101:811-816.
5. Khan MA, Sokoll LJ, Chan DW, et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology. 2004;64:1160-1164.
6. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41-51.
7. Srigley JR, Amin M, Boccon-Gibod L, et al. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005;216:8-19.
8. Schalken JA, Bergh A, Bono A, et al. Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl. 2005;216:82-93.
9. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005;216:34-63.
10. DeMarzo AM, Nelson WG, Isaacs WB, et al. Pathological and molecular aspects ofprostate cancer. Lancet. 2003;361: 955-964.
11. Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl. 2005;216:20-33.
12. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381.
13. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715-717.
14. Stephenson AJ, Scardino PT, Eastham JA, et al. Post-operative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-7012.
15. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.
16. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: impli-cations for diagnosis, detection, prevention, and treatment. J Cell Biochem. 2004;91:459-477.
17. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256-269.
18. Nelson WG, De Marzo AM, Yegnasubramanian S. Epige-netic alterations in human prostate cancers. Endocrinology. 2009;150:3991-4002.
19. Bethel CR, Faith D, Li X, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006;66: 10683-10690.
20. Khan MA, Partin AW. Tissue microarrays in prostate cancer research. Rev Urol. 2004;6:44-46.
21. Diaz JI, Mora LB, Austin PF, et al. Predictability of PSA failure in prostate cancer by computerized cytometric assess- mentoftumoralcellproliferation. Urology. 1999;53:931-938.
22. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110:443-449.
23. BubendorfL, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol. 1998;29:949-954.
24. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156: 1064-1068.
25. Cheng L, Pisansky TM, Sebo TJ, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a markerforprogression. Clin CancerRes. 1999;5:2820-2823.
26. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998;82:168-175.
27. Vis AN, van Rhijn BW, Noordzij MA, et al. Value oftissue markers p27 (kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002;197:148-154.
28. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prosta-tectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma oftheprostate. Cancer. 1997;79:772-779.
29. Strohmeyer D, Rossing C, Strauss F, et al. Tumor angio-genesis is associated with progression after radical prostatec-tomy in pT2/pT3 prostate cancer. Prostate. 2000;42:26-33.
30. Strohmeyer D, Strauss F, Rossing C, et al. Expression of bFGF, VEGF and c-met and their correlation with micro-vessel density and progression in prostate carcinoma. Anti-cancer Res. 2004;24:1797-1804.
31. Gettman MT, Bergstralh EJ, Blute M, et al. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology. 1998;51:79-85.
32. Gettman MT, Pacelli A, Slezak J, et al. Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma. Urology. 1999;54:479-485.
33. Krupski T, Petroni GR, Frierson HF Jr, et al. Microvessel density, p53, retinoblastoma, and chromogranin A immuno-histochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 2000;55:743-749.
34. Zhang YH, Kanamaru H, Oyama N, et al. Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters? Urology. 2000; 55:377-381.
35. Zhang YH, Kanamaru H, Oyama N, et al. Comparison of nuclear morphometric results between needle biopsy and surgical specimens from patients with prostate cancer. Urology. 1999;54:763-766.
36. Veltri RW, Miller MC, Partin AW, et al. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology. 1996;48:685-691.
37. Khan MA, Walsh PC, Miller MC, et al. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer. 2003;98: 2583-2591.
38. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006;66:1203-1212.
39. Sanchez D, Rosell D, Honorato B, et al. Androgen receptor mutations are associated with Gleason score in localized prostate cancer. BJUInt. 2006;98:1320-1325.
40. Theodorescu D, Broder SR, Boyd JC, et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma oftheprostate. Cancer. 1997;80:2109-2119.
41. Weinstein MH, Partin AW, Veltri RW, et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996; 27:683-687.
42. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol. 1997;80:287-290.
43. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells\- a new prognostic parameter in prostate cancer. Br J Urol. 1991;68:258-262.
44. Casella R, Bubendorf L, Sauter G, et al. Focal neuro-endocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol. 1998;160:406-410.
45. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology. 2006;68:2-8.
46. Nakayama M, Bennett CJ, Hicks JL, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture micro-dissection. Am J Pathol. 2003;163:923-933.
47. Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1998;7: 531-536.
48. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol. 2004;46:698-708.
49. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975-1986.
50. Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68:8954-8967.
51. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
52. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396-3400.
53. Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol. 2011.
54. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69: 1400-1406.
55. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596-4599.
56. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcino-mas. Mod Pathol. 2009.
57. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008; 21:1451-1460.
58. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8:230.
59. Mao X, Shaw G, James SY, et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl. 2008;10:467-473.
60. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888.
61. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14: 3395-3400.
62. Falzarano SM, Navas M, Simmerman K, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. ModPathol. 2010;23:1499-1506.
63. Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med. 2012;136:372-390.
64. Netto GJ. TMPRSS2-ERG fusion as a marker of prostatic lineage in small-cell carcinoma. Histopathology. 2010;57:633, author reply 633-634.
65. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarci-noma. Mod Pathol. 2009;22:1415-1422.
66. Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS. 2009;117:575-582.
67. Rice KR, Chen Y, Ali A, et al. Evaluation of the ETS-related gene mRNA in urine for the detection ofprostate cancer. Clin Cancer Res. 2010;16:1572-1576.
68. Nguyen PN, Violette P, Chan S, et al. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol. 2011;59:407-414.
69. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-598.
70. Chaux A, Albadine R, Toubaji A, et al. Immunohistochem-istry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35:1014-1020.
71. Wu Y, Chhipa RR, Cheng J, et al. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010;30:3895-3901.
72. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2010.
73. Bubendorf L. Words of wisdom. Re: aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Eur Urol. 2009;56:882-883.
74. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-1093.
75. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524-526.
76. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15:4799-4805.
77. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet. 2009;41:509-510.
78. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543-1549.
79. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort ofprostate cancer patients. Clin Cancer Res. 2011;17:6563-6573.
80. Armstrong AJ, Netto GJ, Rudek MA, et al. A pharmacody-namic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010;16:3057-3066.
81. Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;161:1238-1243.
82. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biop-sies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162:2040-2045.
83. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511-1516.
84. Bauer JJ, Sesterhenn IA, Mostofi KF, et al. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res. 1995;1:1295-1300.
85. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localizedprostatecancer. Surgery. 1996;120:159-166; discus-sion 166-167.
86. Osman I, Drobnjak M, Fazzari M, et al. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res. 1999;5:2082-2088.
87. Theodorescu D, Broder SR, Boyd JC, et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma oftheprostate. J Urol. 1997;158:131-137.
88. Kuczyk MA, Serth J, Bokemeyer C, et al. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer. 1998;34: 679-686.
89. Markert EK, Mizuno H, Vazquez A, et al. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA. 2011;108:21276-21281.
90. Lacombe L, Maillette A, Meyer F, et al. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer. 2001;95:135-139.
91. Aslan G, Irer B, Tuna B, et al. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006;202:93-98.
92. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. ModPathol. 2008;21:1156-1167.
93. Gurel B, Iwata T, Koh CM, et al. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008;15:319-331.
94. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumori-genesis. Cancer Res. 2007;67:8504-8510.
95. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
96. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11:4097-4106.
97. Bastian PJ, Nakayama M, De Marzo AM, et al. GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer. Urologe. 2004;A43:573-579.
98. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11:4037-4043.
99. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975-5979.
100. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695-2698.
101. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis ofprostate cancer. Clin Chem. 2006;52:1089-1095.
102. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587-1592.
103. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081-1088.
104. Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, ana-lytical performance, and diagnostic accuracy. Clin Chim Acta. 2008;389:1-6.
105. Aubin SM, Reid J, Sarno MJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184:1947-1952.
106. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveil-lance. J Urol. 2008;179:1804-1809; discussion 1809-1810.
107. van Poppel H, Haese A, Graefen M, et al. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJUInt. 2011.
108. Aubin SM, Reid J, Sarno MJ, et al. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology. 2011;78:380-385.
109. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection ofprostate cancer. Cancer Res. 2008;68:645-649.
110. Kantoff P. Recent progress in management of advanced prostatecancer. Oncology (WillistonPark). 2005;19:631-636.
111. Pizer ES, Pflug BR, Bova GS, et al. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 2001;47:102-110.
112. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65:2825-2831.
113. Jimeno A, Carducci M. Atrasentan: a rationally designed targeted therapy for cancer. Drugs Today (Barc). 2006;42: 299-312.
114. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther. 2005;5:419-427.
115. Aggarwal S, Singh P, Topaloglu O, et al. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006;66: 9171-9177.
116. Elsasser-Beile U, Wolf P, Gierschner D, et al. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006;66:1359-1370.
117. Ikegami S, Yamakami K, Ono T, et al. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal anti-body. Hum Gene Ther. 2006;17:997-1005.
118. Jayaprakash S, Wang X, Heston WD, et al. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. Chem Med Chem. 2006;1:299-302.
119. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
120. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. 2004.
121. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2011;9: 41-51.
122. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006;24:5552-5564.
123. Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol. 2010;7:11-20.
124. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics ofbladder cancer. Annu Rev Pathol. 2009;4:251-285.
125. Wu XR. Urothelial tumorigenesis: a tale of divergent path-ways. Nat Rev Cancer. 2005;5:713-725.
126. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol. 2003;170: 1987-1993.
127. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66:7401-7404.
128. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.
129. Kubota Y, Miyamoto H, Noguchi S, et al. The loss of retinoblastoma gene in association with c-myc and trans-forming growth factor-beta 1 gene expression in human bladder cancer. J Urol. 1995;154:371-374.
130. O'Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol. 2007;34:85-97.
131. Eble JN, Sauter G, Epstein JI, et al. The World Health Organization Classification of Tumours of the Urinary System and Male Genital System. Lyon, France: IARC Press; 2004:209-211.
132. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment ofinvasive bladder cancer: long-term results in 1054patients. J Clin Oncol. 2001;19:666-675.
133. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176:2414-2422; discus-sion 2422.
134. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68-75.
135. Rabbani F, Koppie TM, Charytonowicz E, et al. Prognostic significance ofp27(Kip1) expression in bladder cancer. BJU Int. 2007;100:259-263.
136. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778-789.
137. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA micro-arrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973-6980.
138. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003;89:2172-2177.
139. Ioachim E, Michael M, Salmas M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int. 2006;77:255-263.
140. Ioachim E, Michael MC, Salmas M, et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer. 2006;6:140.
141. Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 2006;12:2780-2787.
142. Rotterud R, Nesland JM, Berner A, et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJUInt. 2005;95:1344-1350.
143. Highshaw RA, McConkey DJ, Dinney CP. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). Curr Opin Urol. 2004;14:295-300.
144. Clairotte A, Lascombe I, Fauconnet S, et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker ofneoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol. 2006;125:119-126.
145. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects ofp53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22:1007-1013.
146. Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol. 2007;34:154-164.
147. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;177:481-487; dis-cussion 487.
148. Miyamoto H, Kubota Y, Fujinami K, et al. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. Oncol Res. 1995;7:327-330.
149. Miyamoto H, Kubota Y, Shuin T, et al. Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res. 1993;5:245-249.
150. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol. 2010;57:12-20.
151. Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10: 865-880.
152. Mengual L, Burset M, Ribal MJ, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010;16: 2624-2633.
153. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol. 2007;25:468-475.
154. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther. 2010;10:407-415.
155. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52:1601-1609.
156. Netto GJ. Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med. 2011;135:610-621.
157. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology. 2010;42:384-394.
158. Kawauchi S, Sakai H, Ikemoto K, et al. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol. 2009;40:1783-1789.
159. Kruger S, Mess F, Bohle A, et al. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol. 2003;23: 41-48.
160. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority ofpatients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101-2105.
161. Moonen PM, Merkx GF, Peelen P, et al. UroVysion compared with cytology and quantitative cytology in the surveillance ofnon-muscle-invasive bladder cancer. Eur Urol. 2007;51:1275-1280; discussion 1280.
162. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use ofamultitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006;176:44-47.
163. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301.
164. Fritsche HM, Burger M, Dietmaier W, et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 2010;134:597-603.
165. Karnwal A, Venegas R, Shuch B, et al. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol. 2010;17: 5077-5081.
166. Schlomer BJ, Ho R, Sagalowsky A, et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2010;183:62-67.
167. Ferra S, Denley R, Herr H, et al. Reflex UroVysion testing in suspicious urine cytology cases. Cancer. 2009;117:7-14.
168. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intra-vesical Bacillus Calmette-Guerin therapy. Int J Cancer. 2009;124:2899-2904.
169. Maffezzini M, Campodonico F, Capponi G, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 2010;30:4761-4765.
170. Whitson J, Berry A, Carroll P, et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours under-goingintravesical therapy. BJUInt. 2009;104:336-339.
171. Renshaw AA. UroVysion, urine cytology, and the College of American Pathologists: where should we go from here? Arch PatholLab Med. 2010;134:1106-1107.
172. van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58:433-441.
173. Mason RA, Morlock EV, Karagas MR, et al. EGFR pathway polymorphisms and bladder cancer susceptibility andprognosis. Carcinogenesis. 2009;30:1155-1160.
174. Simonetti S, Russo R, Ciancia G, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohisto-chemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol. 2009;17:198-205.
175. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transi-tional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004;40:56-63.
176. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002;95:1009-1015.
177. Eissa S, Ali HS, Al Tonsi AH, et al. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem. 2005;38:142-148.
178. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955-1959.
179. Leibl S, Zigeuner R, Hutterer G, et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008;116:27-32.
180. Bolenz C, Shariat SF, Karakiewicz PI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothe-lial carcinoma of the urinary bladder. BJU Int. 2010;106: 1216-1222.
181. Al-Ahmadie HA, Iyer G, Janakiraman M, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol. 2011;224:270-279.
182. Ling S, Chang X, Schultz L, et al. An EGFR-ERK-SOX9 Signaling cascade links urothelial development and regener-ation to cancer. Cancer Res. 2011;71:3812-3821.
183. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16: 3011-3018.
184. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recur-rence in non-muscle invasive bladder cancer. Cancer Sci. 2010;101:250-258.
185. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24:3664-3671.
186. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction ofclinical outcome. J Clin Oncol. 2003;21: 1912-1921.
187. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-475; discussion 475-477.
188. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemo-therapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309-317.
189. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7:2440-2447.
190. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progres-sionofinvasivebladdercancer. UrolRes. 1997;25:9-17.
191. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85:53-59.
192. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994;152:388-392.
193. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol. 1995;13:1384-1390.
194. Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer. 2004;100:1859-1867.
195. Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopa-thologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol. 2004;22:112-118.
196. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004;45:606-612.
197. Shariat SF, Bolenz C, Karakiewicz PI, et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:489-495.
198. Lopez-Beltran A, Requena MJ, Luque RJ, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol. 2006;209:106-113.
199. Fu TY, Tu MS, Tseng HH, et al. Overexpression ofp27kip1 in urinary bladder urothelial carcinoma. Int J Urol. 2007;14: 1084-1087.
200. Yin M, Bastacky S, Parwani AV, et al. P16ink4 immunor-eactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2008;39:527-535.
201. Kruger S, Mahnken A, Kausch I, et al. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol. 2005;47: 463-467.
202. Sgambato A, Migaldi M, Faraglia B, et al. Loss ofP27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 1999;59:3245-3250.
203. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315-325.
204. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009; 182:78-84; discussion 84.
205. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol. 2006;59:83-88.
206. Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369-7373.
207. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institu-tional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101:114-119.
208. Ramos D, Ruiz A, Morell L, et al. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms. Anal Quant Cytol Histol. 2004;26:285-294.
209. Cheng L, Zhang S, Maclennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2010.
210. Miyamoto H, Brimo F, Schultz L, et al. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopatho-logic analysis of a post-World Health Organization/Interna-tional Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med. 2010;134:1160-1163.
211. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009;27:3929-3937.
212. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42:978-984.
213. Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol. 2007;34:75-84.
214. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer. 2010.
215. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signa-tures for molecular grading and outcome. Cancer Res. 2010;70:3463-3472.
216. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics. 2008;1:3.
217. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expres-sion profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25:2685-2696.
218. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011;12:137-143.
219. Nishiyama N, Arai E, Chihara Y, et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci. 2010;101:231-240.
220. Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combina-tion analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol. 2010;28:597-602.
221. Vinci S, Giannarini G, Selli C, et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: A prospective, two-center validation study. Urol Oncol. 2009.
222. Cabello MJ, Grau L, Franco N, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. JMolDiagn. 2011;13:29-40.
223. Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst. 2011;103:47-60.
224. Dudziec E, Miah S, Choudhry H, et al. Hypermethylation of CpG Islands and Shores around specific MicroRNAs and Mirtrons is associated with the phenotype and presence of Bladder Cancer. Clin Cancer Res. 2011.
225. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128:1327-1334.
226. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hyper-methylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903-2910.
227. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004;10:7457-7465.
228. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002;8:464-470.
229. Yates DR, Rehman I, Meuth M, et al. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 2006;25:1984-1988.
230. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006;98: 996-1004.
231. Yates DR, Rehman I, Abbod MF, et al. Promoter hyper-methylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13:2046-2053.
232. Ali-El-Dein B, Sarhan O, Hinev A, et al. Superficial bladder tumours: analysis ofprognostic factors and construction of a predictive index. BJU Int. 2003;92:393-399.
233. Loughman NT, Lin BP, Dent OF, et al. DNA ploidy of bladder cancer using bladder biopsy supernate specimens. Anal Quant Cytol Histol. 2003;25:146-158.
234. Baak JP, Bol MG, van Diermen B, et al. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatmentmodality. Urology. 2003;61:1266-1272.
235. Bol MG, Baak JP, Diermen B, et al. Correlation ofgrade of urothelial cell carcinomas and DNA histogram features assessed by flow cytometry and automated image cytometry. Anal Cell Pathol. 2003;25:147-153.
236. Bellaoui H, Chefchaouni MC, Lazrak N, et al. Flow cytometric DNA analysis and cytology in diagnosis and prognosis of bladder tumors: preliminary results of a comparative study of bladder lavage. Ann Urol (Paris). 2002;36:45-52.
237. Caraway NP, Khanna A, Payne L, et al. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer. 2007;111:323-329.
238. Falkman K, Tribukait B, Nyman CR, et al. S-phase fraction in superficial urothelial carcinoma of the bladder\-a pro-spective, long-term, follow-up study. Scand J Urol Nephrol. 2004;38:278-284.
239. Lin J, Dinney CP, Grossman HB, et al. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006;70:240-245.
240. Palit V, Phillips RM, Puri R, et al. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep. 2005;14: 909-913.
241. Chai CY, Chen WT, Hung WC, et al. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol. 2008;61:658-664.
242. Crew JP, O'Brien T, Bicknell R, et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol. 1999;161:799-804.
243. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281-5285.
244. Turner KJ, Crew JP, WykoffCC, et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in super-ficial vs. invasive bladder cancer. Br J Cancer. 2002;86: 1276-1282.
245. Tickoo SK, Milowsky MI, Dhar N, et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJUInt. 2011;107:844-849.
246. Platt FM, Hurst CD, Taylor CF, et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008-6017.
247. Schultz L, Albadine R, Hicks J, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. 2010;116:5517-5526.
248. Comperat E, Camparo P, Haus R, et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch. 2007;450:419-424.
249. Mhawech-Fauceglia P, Fischer G, Beck A, et al. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol. 2006;32:439-444.
250. Veerla S, Panagopoulos I, Jin Y, et al. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer. 2008;47:368-378.
251. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2009.
252. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009;69:8472-8481.
253. Iyer G, Milowsky MI, Bajorin DF. Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10:1917-1932.
254. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol. 2008;18:524-532.
255. Amit D, Tamir S, Birman T, et al. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 2011;4:91-102.
256. Gerullis H, Ecke TH, Janusch B, et al. Long-term res-ponse in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs. 2011.
257. Yafi FA, North S, KassoufW. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011;18:e25-e34.
258. Zhang X, Godbey WT. Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma. Cancer Gene Ther. 2011;18:34-41.
259. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther. 2010;12:607-616.
260. Kramer MW, Krege S, Peters I, et al. Targeted therapy of urological tumours. Experimental field or established ther-apeutic approach? Urologe A. 2010;49:1260-1265.
261. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 2010;90:1406-1414.
262. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer\-an update. Urol Oncol. 2007;25:433-438.
263. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis\- translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26:623-634.
264. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
265. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003;46(suppl):S85-S104.
266. Wallerand H, Robert G, Bernhard JC, et al. Targeted therapy for locally advanced and/or metastatic bladder cancer. Prog Urol. 2008;18:407-417.
267. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzu-mab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25: 2218-2224.
268. Hansel DE, Swain E, Dreicer R, et al. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset ofcases. Am J Clin Pathol. 2008;130:274-281.
269. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor mono-clonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000;6:4874-4884.
270. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257-265.
271. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008;101:20-25.
272. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of cancer and leukemia group B (CALGB) 90102. Ann Oncol. 2009;20:1074-1079.
273. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115: 2881-2890.
274. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525-1530.
275. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009;11:244-249.
276. Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007;5:460-463.
277. Miyamoto H, Miller JS, Fajardo DA, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classi-fication system. Pathol Int. 2010;60:1-8.
278. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73-78.
279. Soloway MS, Sofer M, Vaidya A. Contemporary manage-ment of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-1583.
280. Malekzadeh K, Sobti RC, Nikbakht M, et al. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer. Cancer Invest. 2009;27:70-80.
281. van der Kwast TH, Bapat B. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profil-ing. Curr Opin Urol. 2009;19:516-521.
282. Wilhelm-Benartzi CS, Koestler DC, Houseman EA, et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis. 2010;31:1972-1976.
283. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291.
284. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763-2771.
285. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes ofrenal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
286. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35: 613-625, vii.
287. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005;173:1496-1501.
288. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464-5471.
289. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest. 2008;88:962-972.
290. Hager M, Haufe H, Kemmerling R, et al. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med. 2008.
291. Eichelberg C, Junker K, Ljungberg B, et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009.
292. Djordjevic G, Mozetic V, Mozetic DV, et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract. 2007;203: 99-106.
293. Bensalah K, Pantuck AJ, Crepel M, et al. Prognostic variables to predict cancer-related death in incidental renal tumours. BJUInt. 2008;102:1376-1380.
294. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115:2092-2103.
295. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267.
296. Pantuck AJ, Thomas G, Belldegrun AS, et al. Mammalian target ofrapamycininhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006;33:607-613.
297. Schultz L, Chaux A, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol. 2011;35:1549-1556.
298. Chaux A, Schultz L, Albadine R, et al. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papil-lary cell renal cell carcinomas. Hum Pathol. 2012;43: 2129-2137.
299. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
300. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721.
301. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJUInt. 2004;93:297-302.
302. Lidgren A, Hedberg Y, Grankvist K, et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11:1129-1135.
303. Migita T, Oda Y, Naito S, et al. Low expression ofp27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002;94:973-979.
304. Hedberg Y, Davoodi E, Ljungberg B, et al. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer. 2002; 102:601-607.
305. Hedberg Y, Ljungberg B, Roos G, et al. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer. 2003;88:1417-1423.
306. Kosari F, Parker AS, Kube DM, et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005;11:5128-5139.
307. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13:671s-679s.
308. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004.
309. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
310. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012;24:284-290.
311. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA. 1996;93:10595-10599.
312. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539-542.
313. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
314. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
315. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis ofprognostic factors. Cancer. 2010;116:4256-4265.
316. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
317. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113:1552-1558.
318. Dormoy V, Jacqmin D, Lang H, et al. From development to cancer: lessons from the kidney to uncover new therapeutic targets. Anticancer Res. 2012;32:3609-3617.
319. Maher ER. Genomics and epigenomics of renal cell carci-noma. Semin Cancer Biol. 2012.
320. Kruck S, Bedke J, Kuczyk MA, et al. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2012;12:777-785.
321. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2012.
322. Thillai K, Allan S, Powles T, et al. Neoadjuvant and adjuvant treatment of renal cell carcinoma. Expert Rev Anticancer Ther. 2012;12:765-776.
323. Barrisford GW, Singer EA, Rosner IL, et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol. 2011;2011:658767.
324. Eisengart LJ, MacVicar GR, Yang XJ. Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med. 2012;136:490-495.
325. Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108:1556-1563.
326. Bitting RL, Madden J, Armstrong AJ. Therapy for non-clear cell histologies in renal cancer. Curr Clin Pharmacol. 2011;6:169-180.
327. Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology. 2011;78: 90-98.
328. Bex A, Larkin J, Blank C. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities. Curr Oncol Rep. 2011;13:240-248.
329. Tang PA, Vickers MM, Heng DY. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am. 2011;25:871-891.
330. Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010;16:4853-4863.
331. Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJUInt. 2010;106:772-778.
332. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009.
333. Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol. 2012;53:217-228.
334. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16: 68-73.
335. Ulbright TM, Orazi A, de Riese W, et al. The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. ModPathol. 1994;7:64-68.
336. Baltaci S, Orhan D, Turkolmez K, et al. P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. BJUInt. 2001;87:661-666.
337. Bartkova J, Bartek J, Lukas J, et al. P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer. 1991;49:196-202.
338. Berney DM, Shamash J, Gaffney J, et al. DNA topoisomer-ase I and II expression in drug resistant germ cell tumours. Br J Cancer. 2002;87:624-629.
339. Kersemaekers AM, Mayer F, Molier M, et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol. 2002;20:1551-1561.
340. Sandberg AA, Meloni AM, Suijkerbuijk RF. Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. J Urol. 1996;155:1531-1556.
341. Suijkerbuijk RF, Sinke RJ, Meloni AM, et al. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ-cell tumors revealed by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1993;70:85-93.
342. Cheng L, Zhang S, MacLennan GT, et al. Interphase fluorescence in situ hybridization analysis of chromosome 12p abnormalities is useful for distinguishing epidermoid cysts of the testis from pure mature teratoma. Clin Cancer Res. 2006;12:5668-5672.
343. Looijenga LH, Zafarana G, Grygalewicz B, et al. Role of gain of 12p in germ cell tumour development. APMIS. 2003;111: 161-71; discussion 172-173.
344. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005;18(suppl 2):S51-S60.
345. Rosenberg C, Van Gurp RJ, Geelen E, et al. Overrepresenta-tion of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene. 2000;19:5858-5862.
346. Wehle D, Yonescu R, Long PP, et al. Fluorescence in situ hybridization of 12p in germ cell tumors using a bacterial artificial chromosome clone 12p probe on paraffin-embedded tissue: clinical testvalidation. Cancer Genet Cytogenet. 2008;183:99-104.
347. LeBron C, Pal P, Brait M, et al. Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. Genomics. 2011;97:341-349.
348. Smiraglia DJ, Szymanska J, Kraggerud SM, et al. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene. 2002;21:3909-3916.
349. Netto GJ, Nakai Y, Nakayama M, et al. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol. 2008;21:1337-1344.
350. Brait M, Maldonado L, Begum S, et al. DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br JCancer. 2012;106:414-423.
351. Leman ES, Magheli A, Yong KM, et al. Identification of nuclear structural protein alterations associated with semi-nomas. J Cell Biochem. 2009;108:1274-1279.
352. Eid H, Geczi L, Magori A, et al. Drug resistance and sensitivity ofgerm cell testicular tumors: evaluation ofclinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins. Anticancer Res. 1998;18:3059-3064.
353. Eid H, Institoris E, Geczi L, et al. Mdm-2 expression in human testicular germ-cell tumors and its clinical value. Anticancer Res. 1999;19:3485-3490.
354. Eid H, Van der Looij M, Institoris E, et al. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res. 1997;17:2663-2669.
355. Mayer F, Gillis AJ, Dinjens W, et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res. 2002;62:2758-2760.
356. Mayer F, Stoop H, Scheffer GL, et al. Molecular determi-nants of
357. Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129-2136.
358. Emerson RE, Ulbright TM. Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology. 2010;42:344-355.
359. Dimov ND, Zynger DL, Luan C, et al. Topoisomerase II alpha expression in testicular germ cell tumors. Urology. 2007;69:955-961.
360. Mazumdar M, Bacik J, Tickoo SK, et al. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prog-nostic subgroup within the embryonal carcinoma germ cell tumor. J Clin Oncol. 2003;21:2679-2688.
361. Wang X, Zhang S, Maclennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. Mod Pathol. 2009;22:7-12.
362. Biermann K, Goke F, Nettersheim D, et al. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol. 2007;213:311-318.
363. Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review ofliterature. Genes Chromosomes Cancer. 2008;47:34-42.
364. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol. 2004;164: 305-313.
365. Nikolaou M, Valavanis C, Aravantinos G, et al. Kit expression in male germ cell tumors. Anticancer Res. 2007;27:1685-1688.
366. Willmore-Payne C, Holden JA, Chadwick BE, et al. Detec-tion of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. Mod Pathol. 2006;19:1164-1169.
367. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255-261.